Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Plasma cell 3Other hematologic neoplasm 3Breast 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Multiple Myeloma 3Lymphoma, Non-Hodgkin 2Leukemia, B-Cell 1

Interventions

Dexamethasone 139Lenalidomide 75Cyclophosphamide 73Bortezomib 73Calcium Dobesilate 57fludarabine 49pomalidomide 43daratumumab 39fludarabine phosphate 34carfilzomib 33Melphalan 29dexamethasone acetate 24dexamethasone 21-phosphate 24auricularum 22Filgrastim 18Whole-Body Irradiation 15Biopsy 14ixazomib 13isatuximab 13Magnetic Resonance Spectroscopy 13Granulocyte Colony-Stimulating Factor 13Vorinostat 12Tacrolimus 12Specimen Handling 12Sirolimus 12Peripheral Blood Stem Cell Transplantation 12venetoclax 11belantamab mafodotin 11Rituximab 11Panobinostat 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × dinaciclib × Plasma cell × Clear all
NCT01711528 2018-05-11

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
Plasma cell

Multiple Myeloma

NCT00871910 2017-10-23

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Merck Sharp & Dohme LLC

Phase 1 Completed
81 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00871663 2015-04-20

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Merck Sharp & Dohme LLC

Phase 1 Completed
123 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡